Adam Snook received a B.S. in Pharmacology and Toxicology (2001) from the University of the Sciences and a Ph.D. in Immunology and Microbial Pathogenesis (2008) from Thomas Jefferson University.

Dr. Snook was a founding member and served as the Director of Antibody Development for 5 years at Invisible Sentinel, Inc. a leading molecular solutions company specializing in food safety and a current subsidiary of bioMérieux.

He joined the faculty at Thomas Jefferson University in 2013 in the Department of Pharmacology and Experimental Therapeutics where he is studying the mechanisms underlying colorectal cancer tumorigenesis and the interaction between cancer and the immune system to develop new options to prevent or treat gastrointestinal cancers. His work has led to 7 investigator-initiated clinical trials examining colorectal cancer chemoprevention, cancer vaccines, and CAR-T cell therapies.

Dr. Snook has authored over 100 book chapters and papers in prestigious journals, including Cancer Research, Gastroenterology, Journal of Clinical Investigation, Journal for Immunotherapy of Cancer (JITC), Cancer Immunology Research, and Cancer Cell, and his work has been featured in Nature Outlook, US News and World Report, Forbes, Reuters, the Washington Post, the New York Times, the Philadelphia Inquirer, and others.

He is currently an Associate Professor in the Department of Pharmacology and Experimental Therapeutics with a secondary appointment in the Department of Microbiology and Immunology. He is an Assistant Program Leader of the Immune Cell Regulation and Targeting (IRT) Program of the Sidney Kimmel Cancer Center. He is also Director of the Clinical & Translational Research track of the JeffMD Scholarly Inquiry Program of the Sidney Kimmel Medical College.